Iris Freya Chaberny

Iris Freya Chaberny

Auto-generated profile, based on publicly available information

Iris Freya Chaberny

University of Leipzig Medical Center, Institute of Hygiene, Hospital Epidemiology and Environmental Health, Leipzig, Germany

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2003 in Chemosphere
Verified
Journal Article
Closed access
KKKlaus P. Kühn
Klaus P. Kühn
ICIris F. Chaberny
Iris F. Chaberny
KMKarl Massholder
Karl Massholder
MSManfred Stickler
Manfred Stickler
VBVolker W. Benz
Volker W. Benz
LELothar Erdinger
Lothar Erdinger

5 January 2018 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
LPLaura Puchter
Laura Puchter
ICIris Freya Chaberny
Iris Freya Chaberny
FSFrank Schwab
Frank Schwab
RVRalf-Peter Vonberg
Ralf-Peter Vonberg
FBFranz-Christoph Bange
Franz-Christoph Bange
EEElla Ebadi
Ella Ebadi
Background: Nosocomial infections due to vancomycin-resistantenterococci(VRE) have become a major problem during the last years. The purpose of this study was to investigate the economic burden of nosocomial VRE infections in a European university hospital.Methods: A retrospective matched case-control study was performed including patients who acquired nosocomial infection with either VRE or vancomycin-susceptible enterococci (VSE) within a time period of 3 years. 42 cases with VRE infections and 42 controls with VSE infections were matched for age, gender, admission and discharge within the same year, time at risk for infection, Charlson comorbidity index (±1), stay on intensive care units and non-intensive care units as well as for the type of infection, using criteria of the Centers for Disease Control and Prevention.Results: The median overall costs per case were significantly higher than for controls (EUR 57,675 vs. EUR 38,344;p = 0.030). Costs were similar between cases and controls before onset of infection (EUR 17,893 vs. EUR 16,600;p = 0.386), but higher after onset of infection (EUR 37,971 vs. EUR 23,025;p = 0.049). The median attributable costs per case for vancomycin-resistance were EUR 13,157 (p = 0.036). The most significant differences in costs between cases and controls turned out to be for pharmaceuticals (EUR 6030 vs. EUR 2801;p = 0.008) followed by nursing staff (EUR 8956 vs. EUR 4621;p = 0.032), medical products (EUR 3312 vs. EUR 1838;p = 0.020), and for assistant medical technicians (EUR 3766 vs. EUR 2474;p = 0.023). Furthermore, multivariate analysis revealed that costs were driven independently by vancomycin-resistance (1.4 fold;p = 0.034).Conclusions: This analysis suggested that nosocomial VRE infections significantly increases hospital costs compared with VSE infections. Therefore, hospital personal should implement control measures to prevent VRE transmission.

1 April 2010 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
KGKarolin Graf
Karolin Graf
EOElla Ott
Ella Ott
RVRalf-Peter Vonberg
Ralf-Peter Vonberg
CKChristian Kuehn
Christian Kuehn
AHAxel Haverich
Axel Haverich
ICIris Freya Chaberny
Iris Freya Chaberny
Surgical-site infections are a very expensive complication in cardiac surgery. Thus, the total costs for coronary artery bypass grafting (CABG) surgery may substantially increase when a deep sternal wound infection (DSWI) occurs. This may be due to an extended length of stay (LOS), the need for additional surgical procedures, vacuum-assisted wound dressing and antibiotic therapy. This study compares the LOS in the hospital and on an intensive care unit (ICU) as well as the total costs for patients undergoing CABG depending upon the occurrence of a subsequent DSWI. A case-control study was performed. Total costs of DSWI cases were analysed and compared to patients undergoing CABG without DSWI. Inclusion criterion for cases was the development of a DSWI according to the CDC criteria during hospital stay after CABG. Two control patients without any signs or symptoms of an infection during hospital stay were matched to each case by (1) type of surgery according to their diagnosis-related group (DRG), (2) age +/-5 years, (3) gender and (4) duration of preoperative hospital stay +/-2 days, but at least as long as the time at risk of cases before infection. Between January 2006 and March 2008, 17 CABG patients with DSWI (cases) and 34 matched controls were included. The median overall costs of a CABG case were 36,261 Euro compared with 13,356 Euro per control patient without infection (p<0.0001). The median overall LOS was 34.4 days versus 16.5 days, respectively (p=0.0006). The median LOS on ICU was 6.3 days versus 5.3 days (no significant difference). DSWI represents an important economic factor for the hospital as they may almost triple the costs for patients undergoing CABG. Thus, appropriate infection control measures for the prevention of DSWI should be enforced.

1 March 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SBSebastian Bruchmann
Sebastian Bruchmann
ADAndreas Doetsch
Andreas Doetsch
BNBianka Nouri
Bianka Nouri
ICIris F. Chaberny
Iris F. Chaberny
SHSusanne Häussler
Susanne Häussler
Quinolone antibiotics constitute a clinically successful and widely used class of broad-spectrum antibiotics; however, the emergence and spread of resistance increasingly limits the use of fluoroquinolones in the treatment and management of microbial disease. In this study, we evaluated the quantitative contributions of quinolone target alteration and efflux pump expression to fluoroquinolone resistance in Pseudomonas aeruginosa . We generated isogenic mutations in hot spots of the quinolone resistance-determining regions (QRDRs) of gyrA , gyrB , and parC and inactivated the efflux regulator genes so as to overexpress the corresponding multidrug resistance (MDR) efflux pumps. We then introduced the respective mutations into the reference strain PA14 singly and in various combinations. Whereas the combined inactivation of two efflux regulator-encoding genes did not lead to resistance levels higher than those obtained by inactivation of only one efflux regulator-encoding gene, the combination of mutations leading to increased efflux and target alteration clearly exhibited an additive effect. This combination of target alteration and overexpression of efflux pumps was commonly observed in clinical P. aeruginosa isolates; however, these two mechanisms were frequently found not to be sufficient to explain the level of fluoroquinolone resistance. Our results suggest that there are additional mechanisms, independent of the expression of the MexAB-OprM, MexCD-OprJ, MexEF-OprN, and/or MexXY-OprM efflux pump, that increase ciprofloxacin resistance in isolates with mutations in the QRDRs.

24 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CBClaas Baier
Claas Baier
LLLena Linke
Lena Linke
MEMatthias Eder
Matthias Eder
FSFrank Schwab
Frank Schwab
ICIris Freya Chaberny
Iris Freya Chaberny
EEElla Ebadi
Ella Ebadi
Non-implanted central vascular catheters (CVC) are frequently required for therapy in hospitalized patients with hematological malignancies or solid tumors. However, CVCs may represent a source for bloodstream infections (central line-associated bloodstream infections, CLABSI) and, thus, may increase morbidity and mortality of these patients. A retrospective cohort study over 3 years was performed. Risk factors were determined and evaluated by a multivariable logistic regression analysis. Healthcare costs of CLABSI were analyzed in a matched case-control study. In total 610 patients got included with a CLABSI incidence of 10.6 cases per 1,000 CVC days. The use of more than one CVC per case, CVC insertion for conditioning for stem cell transplantation, acute myeloid leukemia, leukocytopenia (≤ 1000/μL), carbapenem therapy and pulmonary diseases were independent risk factors for CLABSI. Hospital costs directly attributed to the onset of CLABSI were 8,810 € per case. CLABSI had a significant impact on the overall healthcare costs. Knowledge about risk factors and infection control measures for CLABSI prevention is crucial for best clinical practice.

1 October 2008 in Journal of Hospital Infection
Verified
Journal Article
Closed access
PGPetra Gastmeier
Petra Gastmeier
DSDorit Sohr
Dorit Sohr
FSFrank Schwab
Frank Schwab
MBMichael Behnke
Michael Behnke
IZIrina Zuschneid
Irina Zuschneid
CGChristine Geffers
Christine Geffers